TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.120
-0.010 (-0.88%)
At close: Mar 6, 2026, 4:00 PM EST
1.090
-0.030 (-2.68%)
After-hours: Mar 6, 2026, 7:23 PM EST
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 8.00, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 614.29% from the current stock price of 1.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +346.43% | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +525.00% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +435.71% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +792.86% | May 7, 2025 |
Financial Forecast
Revenue This Year
8.03M
from 10.33M
Decreased by -22.20%
Revenue Next Year
13.64M
from 8.03M
Increased by 69.75%
EPS This Year
-0.91
from -1.00
EPS Next Year
-0.87
from -0.91
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.5M | 17.4M | |||
| Avg | 8.0M | 13.6M | |||
| Low | n/a | 10.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 60.2% | 116.2% | |||
| Avg | -22.2% | 69.7% | |||
| Low | - | 24.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.69 | -0.57 | |||
| Avg | -0.91 | -0.87 | |||
| Low | -1.45 | -1.06 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.